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move, but some had ascites, pleural effusion, jaundice, dyspnea (3-10%), and used
narcotic (13%). At first visit, as old as age 97 received care (mean age 54.8/14.3;
ranged 1-97), and lung, hepatobiliary, colon, gastric, breast and pancreatic cancer
were comprised of 80% of cancers. Among these about 40-50% had poor perfor-
mance status (ECOG 2-4). CONCLUSIONS: In consideration of the size of the center
and non-insured, offering cytostatic therapy received with remarkable attention by
the patients previously treated with cytotoxic therapy. Further research is needed
to investigate cons and pros of cytostatic therapy.
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OBJECTIVES: In some BCC patients, tumors may progress to locally advanced dis-
ease or become metastatic (aBCC). BCCNS (Gorlin syndrome) is a rare genetic con-
dition associated with life-long occurrence of multiple BCCs. Surgical treatments
may cause disfiguring scars. The patient experience for those with aBCC and BC-
CNS is not well understood. Qualitative research was conducted to develop a PRO
questionnaire for this population. METHODS: Concept elicitation interviews were
conducted in aBCC or BCCNS patients  18 yr and physicians using an interview
guide containing open-ended questions about symptom impact on functioning
and well-being. Results from patient interviews were used to develop draft ques-
tionnaires. Cognitive debriefing interviews were conducted to finalize the
questionnaires. RESULTS: Thirty patients were interviewed [14 aBCC (8 locally
advanced and 6 metastatic; 73% male, mean age 64) and 16 BCCNS (50% male, mean
age 51)]. Patients experience a variety of disease symptoms including pain, swell-
ing, bleeding, and itching. Physical appearance, specifically scarring and disfigure-
ment, affected 73% of patients. 80% of patients made lifestyle changes (avoided
outdoor activities and intimate relationships). Emotional effects, including worry
about when/where the next BCC would appear, were evident in BCCNS patients
(80%). Physicians (n4) noted aBCC patients worry about cancer and the possibility
of more tumors, while BCCNS patients are concerned about tumor recurrence,
multiple surgeries and disfigurement. Based on interview results, separate aBCC
and BCCNS questionnaires were developed. Ten cognitive-debrief interviews were
conducted to evaluate content and clarity of draft questionnaires. The question-
naires were easy to complete and items were relevant. Minor revisions were made.
The final questionnaires include questions about symptoms, appearance, emo-
tions, worry, lifestyle changes, concerns, and treatment satisfaction.
CONCLUSIONS: There are significant and unique impacts to appearance, daily and
emotional functioning, and HRQoL in aBCC and BCCNS patients. An ongoing vali-
dation study will examine psychometric properties of the questionnaires.
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OBJECTIVES: FDA and EMA have created guidelines for PRO label claims. However,
there have been few PRO-based label claims in oncology (Gnanasakthy, et al., 2012)
since the release of the FDA guidelines. The objective of this research was to ex-
plore factors that might predict regulatory success for PROs. We developed a reg-
ulatory success gradient, and used factors based on literature review, expert inter-
views, and the FDA Guidances to predict success. METHODS: Using a case-control
approach, 10 oncology medications with PRO labels came from two sources: 1) a
review of PROs in oncology labels (Gondek et al, 2007), and 2) a proprietary database
(http://www.mapi-prolabels.org/) containing a list of PRO-based labels. Six controls
were oncology medications with the same indication and mechanism of action, but
without PRO data in the label. Regulatory success was defined from none (no PRO in
the label), through minimal, mild, and moderate, to great success (PRO labeling in
the indication section). Independent factors, derived from literature review, expert
interviews, and the PRO Guidances, possibly related to regulatory success included
conceptual fit, study quality, conformity to PRO Guidance (content validity), psy-
chometrics score, and other PRO characteristics, were evaluated. RESULTS: No
medication achieved great PRO labeling success. Only three medications achieved
moderate regulatory success, seven achieved mild, and five achieved minimal suc-
cess. None of the factors identified as potentially related to regulatory success were
significantly correlated with it (Spearman correlations): Other PRO Characteristics
(0.33), Conceptual Fit (0.09), Study Quality (-0.13), Psychometrics (-0.18), and Con-
formity to the PRO Guidance (0-0.02). CONCLUSIONS: Despite widespread use of
PROs in oncology, very few labels actually include PRO-based results, and further-
more, no medications achieved great success and only three moderate success in
labeling. Based on our regulatory success gradient, driving factors leading to regu-
latory success have yet to be identified.
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OBJECTIVES: Lung cancer is one of the most common high incidence and mortality
cancers. Many lung cancer patients (LCPs) receive chemotherapy not only for cu-
rative treatment, but also to palliate symptoms and maintain or even improve their
quality of life (QOL). Though the impact of substances and duration of chemother-
apy on progression-free and overall survival is intensively investigated, there is
currently only little knowledge on patients’ QOL in regard to the number of CT-lines
administered. METHODS: By means of computer-based patient-reported outcome
monitoring LCPs receiving ambulant chemotherapy (adjuvant or palliative) com-
pleted the internationally validated EORTC QLQ-C30, supplemented by two addi-
tional questions concerning taste alterations. Statistical analysis comprised mixed
linear models to calculate change rates over time and differences between chemo-
therapy lines. RESULTS: A total of 175 LCPs (32% female, on average 68 years old (
10.4 SD) and 5 ( 4.5 SD) assessments/patient) participated in repeated QOL-assess-
ment during ambulant chemotherapy administration. Twenty percent of LCPs re-
ceived adjuvant chemotherapy, 73.1% 1st line palliative chemotherapy and 6.9% 2nd
or above line chemotherapy. 70.7% were diagnosed with NSCLC, 21.0 % with SCLC
and 8.3% with other types of lung cancer. Symptom trajectories during adjuvant
chemotherapy did not show a significant change in QOL-scores. LCPs receiving 1st
line palliative chemotherapy experienced improvement concerning sleep distur-
bances (-1.9 points/month, p.009), but deteriorations in regard to appetite loss
and taste alterations (2.8 points/month, p.001, respectively), constipation (1.8
points/month, p.020) and financial impact (1.3 points/month, p.038); 2nd or
above line palliative chemotherapy was associated with stronger symptom burden
than adjuvant or 1st line palliative chemotherapy in most of the EORTC QLQ-C30
domains (e.g. physical, emotional and cognitive functioning, pain and appetite
loss). CONCLUSIONS: Though aggressive, adjuvant treatment did not endanger
patients’ QOL. 1st line palliative chemotherapy proved to be helpful in maintaining
and stabilizing patients’ QOL, since deteriorations have been limited.
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Appropriate utility values for disease states in metastatic castration-resistant pros-
tate cancer (mCRPC) have been contentious in recent economic models submitted
to NICE and other HTA bodies. The validity of mapping algorithms beyond the
range of original data in less symptomatic patients and the evolution of utility once
life-extending treatments have failed, were both considered areas of uncertainty.
OBJECTIVES: To construct and validate a prediction model of preference-adjusted
health status (EQ-5D) for metastatic castration-resistant prostate cancer (mCRPC)
patients using FACT-P (Functional Assessment of Cancer Therapy–Prostate).
METHODS: Observational study conducted in 47 centres across 6 countries (Bel-
gium, France, Germany, Sweden, The Netherlands, UK) collected HRQoL data for
699 patients with confirmed mCRPC and documented disease progression. Utility
values were derived from EQ-5D profiles based on a UK-specific EQ-5D value set (1).
Predictive validity of the 5 FACT-P subscales, patient demographics, co-morbidities
and prior chemotherapy for utility values was tested using ordinary least square
(OLS), median, Gamma and Tobit multivariate regression models. RESULTS: At the
time of assessment, mean age, mean time since diagnosis and failure on androgen-
deprivation therapy were 72.1, 6.6 and 4.1 years respectively; 32% of patients were
treated with chemotherapy, 24% had prior chemotherapy, and 43% were chemo-
therapy naive. At diagnosis, 35.9% of patients had metastases and 84.1% had Glea-
son score 7. Mean FACT-P and EQ-5D utility were 104.0 and 0.67 respectively.
OLS-regression was the best-performing model, explaining 61% of the observed
EQ-5D variation. All FACT-P subscales were significantly predictive. The physical
(coefficient0.023,p0.0001) and functional (0.011,p0.0001) well-being subscales
had the highest explanatory value. Age, co-morbidities and prior chemotherapy
did not add additional explanatory value. CONCLUSIONS: The developed algo-
rithms enable translation of cancer-specific health-related quality of life measures
to preference-adjusted health status in mCRPC-patients. Findings will help to de-
velop health status adjustments in cost-utility analyses used in future HTA’s.
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OBJECTIVES: Malignant ascites (MA) is associated with poor prognosis and limited
palliative therapeutic options. Therefore a change in patients’ health-related qual-
ity of life (HRQoL) is of particular importance to demonstrate added value of a new
treatment to the patient-reported outcomes (PRO). Moreover how fast the change
occurs can be as important as the simple occurrence of a meaningful change in
HRQoL. Following demonstration of superiority on puncture-free survival of catu-
maxomab plus paracentesis vs paracentesis alone, this study aimed to compare
time to deterioration in HRQoL between both treatment groups by using survival
analysis techniques.METHODS: In a randomized, multi-center, phase II/III study in
patients with MA, HRQoL was measured by using the European Organization for
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Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30),
a PRO instrument specifically designed to measure HRQoL of cancer patients.
HRQoL was measured at screening, months 1, 3, 7, and at re-puncture. Meaningful
deterioration was defined as a decrease in HRQoL scores of at least 5 points. Time
to first meaningful deterioration was compared between catumaxomab (N160)
and control (N85) groups using survival analysis techniques such as log-rank test
and Cox models. RESULTS: Deterioration in HRQoL scores appeared more rapidly
in the control group than the catumaxomab group (medians: 16-28 days vs. 45-49
days). The difference between the two groups in time to deterioration in HRQoL
was statistically significant for all scores (p0.01). Results were confirmed with Cox
models (p0.05). Hazard ratios ranged from 0.08 to 0.24.CONCLUSIONS:Treatment
with catumaxomab delayed deterioration in HRQoL in patients with MA compared
to paracentesis alone. The findings of this study indicate that the gain of puncture
free survival due to catumaxomab treatment previously reported (Heiss et al. 2010)
translates into a HRQoL benefit for the patients.
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OBJECTIVES: The majority of patients with prostate cancer progress to CRPC and
frequently develop bone metastases. Treatment and management of bone metas-
tases, as well as the underlying disease, influences the patient’s quality of life. We
evaluated the impact of bone metastases on utility (using EQ-5D) and quality of life
(using FACT-P) in high-risk CRPC patients. METHODS: Data were extracted from
the Adelphi Real World Prostate Cancer Disease-Specific Programme© (DSP), a
cross-sectional survey of 348 urologists and oncologists and their prostate cancer
patients that was conducted between December 2009 and May 2010 in France,
Germany, Italy, Spain and the UK. Physicians completed comprehensive record
forms on 10 patients being actively treated for prostate cancer. Patients could also
complete a questionnaire, which included the EQ-5D and FACT-P tools, however
this was not compulsory. RESULTS:Of the 3,477 prostate cancer patients for which
data were collected, 1,180 (34%) were categorised as having CRPC with a median
time since diagnosis of 35.8 months. 146 patients with CRPC were identified as
being at high risk for developing bone metastases (Gleason score 8, or a most
recent PSA of 8ng/mL, or a PSA DT 10 months, or had received local therapy in
addition to systemic medication). High-risk CRPC patients had an average EQ-5D
index of 0.77 (n36) and FACT-P of 99.54 (n27). In contrast, patients with CRPC
and bone metastases (n680) had an average EQ-5D index of 0.59 (n165) and
FACT-P of 82.99 (n147). Statistical differences were observed between the high-
risk and bone metastases groups for both EQ-5D (p0.0002) and FACT-P (p0.0007).
CONCLUSIONS: The development of bone metastases represents a significant ad-
ditional burden for patients with CRPC highlighting the need for new treatments
capable of preventing bone metastases in these patients.
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OBJECTIVES: (1) To identify antineoplastic agents approved with a PRO labeling
claim in Europe and the USA; (2) To review the types of PROs used for these ap-
provals; and (3) To list the differences found between Europe and the USA in terms
of products and labeling. METHODS: The search was performed on the FDA and
EMA approved medicinal product labels (from 1995 to 2010). The review was con-
ducted through a systematic manual review of antineoplastic product labelings. All
documents were read individually by two independent raters. RESULTS: A total of
138 antineoplastic products were retrieved: 55 approved by the EMA, 83 by the FDA.
Nineteen products with a PRO claim were identified: eight the USA, 11 in Europe.
Most of the PROs identified in the claims were symptoms or function. HRQL was
mentioned for 11 products: nine in Europe, two in the USA. PROs were primary
endpoints in two cases (advanced cancers). Nine products approved by both agen-
cies showed discrepancies in terms of PRO labeling: the EMA gave a PRO claim to
eight products, but not the FDA; and the FDA gave a PRO claim to one product, but
not the EMA. In most cases, the reviews of both agencies were conducted on the
same material. The comparison of the products with a PRO labeling claim approved
by the EMA but refused by the FDA showed that the FDA questioned the quality of
the study design, the analyses, or the questionnaires’ content validity.
CONCLUSIONS: Our review showed that the patients’ perspective in clinical onco-
logic research is important for the EMA and FDA. However, the patients’ perspec-
tive is not considered sufficient on its own: PROs are rarely used as primary end-
points except for assessing palliative response. Our analysis suggests that there is
high receptivity of EMA to HRQL as a concept.
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Treatment of metastatic castration-resistant prostate cancer (mCRPC) is primarily
palliative and patients’ quality of life (QoL) is considered an important treatment
goal. Nevertheless, little is known about QoL of mCRPC patients. OBJECTIVES: To
assess QoL outcomes in mCRPC patients in Germany. METHODS: 1-year observa-
tional, cross-sectional, prospective study conducted in Germany by 37 prostate-
cancer (PC) specialised centres. The study included patients with confirmed PC
diagnosis and metastatic castration-resistant disease. EQ-5D and FACT-P ques-
tionnaires were completed by patients at inclusion visit. Patient characteristics
were collected by physicians. Interim results based on 101 of 281 patients in total,
are presented. RESULTS: Mean age was 73.2 years. At inclusion, 32.6% had never
been treated with chemotherapy (no CT), 36.8% had been treated with chemother-
apy previously (past CT) and 30.5% were currently undergoing chemotherapy (on-
going CT). Mean time since PC diagnosis was 7.2 years (respectively 8.7, 6.6 and 4.0
years for no CT, past CT and ongoing CT). 34.0% of patients had metastases at
diagnosis. Mean (SD) EQ-5D single index utility score was 0.72 (0.30) (respectively
0.81 (0.27), 0.66 (0.30), 0.64 (0.31) for no CT, past CT and ongoing CT). 67.3% of
patients exhibited pain or discomfort, 58.1% problems to perform usual activities,
53.1% mobility problems, 37.7% anxiety/depression troubles and 32.7% self-care
problems. Mean (SD) EQ-5D VAS score was 47.8 (23.6). Mean (SD) FACT-P total score
was 101.5 (25.2) (respectively 106.0 (27.1), 95.2 (21.6) and 103.5 (26.7) for no CT, past
CT and ongoing CT). Mean (SD) subscale scores were: physical well-being: 19.5 (6.6),
social/family well-being: 20.6 (5.6), emotional well-being: 17.0 (4.8), functional well-
being: 15.7 (6.3) and PC subscale: 28.6 (9.0). CONCLUSIONS: The interim analysis
provides first trends on QoL in German mCRPC patients. Final analyses are ex-
pected to clarify determinants of QoL and in particular the impact of chemother-
apy.
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OBJECTIVES: The incidence of acute myeloid leukaemia (AML) increases with age;
older patients have limited treatment options and poorer outcomes. Dependence
on blood transfusions (correcting anaemia and preventing bleeding) and repeated
hospitalisation reduce health-related quality of life and increase treatment expen-
diture. This post-hoc analysis assessed the impact of decitabine on transfusion
dependence.METHODS:The DACO-16 phase III trial (NCT00260832) was conducted
in newly-diagnosed AML patients (65 years; N485) (Kantarjian, JCO; ePub
11Jun2012). Every 4 weeks, patients received decitabine (DACOGEN) 20 mg/m2 (1-h
intravenously; 5 successive days) or treatment choice with physician’s advice (TC)
with supportive care or cytarabine (20 mg/m2 subcutaneously daily; 10 successive
days). Treatment duration was longer in the DACOGEN than TC arm (median: 4
cycles vs. 2 cycles). We measured red blood cell (RBC) and platelet (PLT) transfu-
sion-independence (no transfusions for 8 consecutive weeks) and hospitalisation
length (% hospital nights relative to treatment days) in both DACOGEN (n242) and
TC (n243) arms. RESULTS: In patients who were PLT transfusion-dependent at
baseline (85 in DACOGEN and 83 in TC arms), more became transfusion-indepen-
dent in the DACOGEN arm (26 [31%]) than the TC arm (11 [13%]) (p0.0069). Like-
wise, in RBC transfusion-dependent patients at baseline (168 in DACOGEN and 162
in TC arms), transfusion-independence was higher for DACOGEN (44 [26%]) than TC
(21 [13%]) (p0.0026). For hospitalised patients (182 in TC, 191 in DACOGEN arms),
the median % of hospital nights was higher in the TC arm (39%) than the DACOGEN
arm (34%). Similarly, for adverse event-hospitalised patients (100 in TC, 132 in
DACOGEN arms), the median was 20.0% vs. 17.5% in the TC and DACOGEN arms,
respectively. CONCLUSIONS: Dacogen leads to a statistically-significant reduction
in transfusion-dependence, when compared with TC. This reduction is an impor-
tant factor in the economic and humanistic burden of AML in older patients.
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OBJECTIVES: G-CSFs can decrease the incidence of febrile neutropenia (FN) among
cancer patients receiving highly myelosuppressive chemotherapy regimens. The
primary objective of this pilot study was to determine the feasibility of a discrete
choice survey on prophylactic G-CSF (pegfilgrastim and filgrastim) use in patients
diagnosed with breast cancer as well as refine the survey instrument before pro-
ceeding with the full study population. METHODS: A web-based discrete choice
survey of patients diagnosed with breast cancer, and previously treated with che-
motherapy, was conducted. The pilot survey was developed based on literature
review, clinical consultation and 6 in-depth and 4 pre-test interviews with breast
cancer patients. The experimental design was generated using Sawtooth software
with 16 paired treatment-scenarios, comparing pegfilgrastim to filgrastim at 6- or
11-doses with a follow-up “no treatment” option. The 5 attributes included: fre-
quency of treatment, inconvenience of treatment, risk of disruption to chemother-
apy schedule due to low white blood cell counts, risk of developing an infection
requiring hospitalization, and patient out-of-pocket cost. Demographics, clinical
characteristics, health care costs and attitudinal data were also collected.
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